Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-6450 SAD/MAD study in healthy subjects
NCT02022306Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Feb 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TD-6450 in hepatitis C (HCV) (3 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Adverse events. Started Feb 2014; status: completed.
02
Drugs
TD-6450
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02022306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022306.